ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...

Related Keywords

Canada ,United States ,California ,Vancouver ,British Columbia ,Canadian ,David Parkinson ,Andrew Laccetti ,Drug Administration ,Memorial Sloan Kettering Cancer Center ,Pharma Inc ,Twitter ,Prostate Cancer Foundation Scientific ,Linkedin ,Prostate Cancer Foundation Scientific Retreat ,Enz Alone ,Metastatic Castration Resistant Prostate Cancer ,Current Phase ,Memorial Sloan Kettering Cancer ,Fast Track ,Private Securities Litigation Reform Act ,